NEW DELHI, 15 SEP. The Indian drug regulator has approved the third phase of trials of the Russian coronavirus vaccine Sputnik Light, according to the Economic Times, citing sources. , as well as the durability of antibodies to a subject expert committee that advises the regulatory body, «the publication reports. The single-component Sputnik Light vaccine was registered in Russia in early May, its effectiveness was 79.4%, which is higher than that of many vaccines requiring two injections. Sputnik Light is the first component of the Sputnik V vaccine. No serious adverse events were reported after immunization with the drug. Previously, the Indian authorities approved five vaccines against coronavirus — a local version of the «Oxford» vaccine from AstraZeneca called Covieshield, domestic Covaxin and ZyCoV-D, the Russian Sputnik V vaccine and the American vaccine produced by Moderna India remains the world's second most diagnosed coronavirus case. According to the latest data from the Ministry of Health, since March last year, when the pandemic began in the country, the total number of people infected with coronavirus in India exceeded 33.3 million, more than 32.5 million have recovered, more than 443 thousand have died, and the number of people receiving treatment is 351 thousand.
Argentina evaluated the effectiveness of «Sputnik Light» in the elderly
